Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

Participants needed: 154
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Xiaotong HouUpdated: Apr 6, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years old [+3]

previous history of allergy to heparin or bivalirudin [+5]

Status: Recruiting

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.

Participants needed: 80
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Xiaotong HouUpdated: Sep 25, 2025Locations: 1
Eligibility criteria

Age ≥ 18 years old [+3]

The researchers believe that there are other causes of active bleeding that are... [+9]

Status: Recruiting

Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.

Participants needed: 534
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Xiaotong HouUpdated: Mar 6, 2025Locations: 1Duration: 30 Days
Eligibility criteria

Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support. [+2]

Age <18 years. [+3]